Neonatal sepsis is a leading cause of death in newly born babies resulting from a bloodstream infection caused by a variety of bacterial pathogens. Despite increased hygiene practices, LOS incidence has paradoxically increased in the past forty years due to an increase in cases resulting from commensal species from the of the normal skin and intestinal flora. Intriguingly, in a substantial portion of LOS, the pathogen can be found as a resident of the neonatal gut microbial community prior to disease, yet it remains unclear how bacterial pathogens translocate from the intestine and how the neonatal immune system initially reacts to gut originating pathogen translocation. In my preliminary studies, I have shown gut residing bacteria can translocate the epithelium via goblet cells forming goblet cell associated antigen passages (GAPs) and require CX3CR1 mononuclear phagocytes (MNPs) to gain access to the circulation. Bacterial translocation prior to day of life 10 is inhibited by maternally supplied proteins in breastmilk. Asynchronous cross-fostering (ACF) of 1 day old pups to dams having delivered a litter 10 days prior results in bacterial translocation between DOL1- DOL10. Both commensal bacteria and pathogenic clinical sepsis-causing isolates could translocate and gain systemic access physiologically In ACF mice. However, only mice gavaged with pathogenic E.coli succumbed to a sepsis-like disease following translocation of pathogenic E.coli, despite similar bacteria burden when compared to ACF mice with commensal E. coli. ACF mice with pathogenic E.coli, developed an inflammatory signature in the intestinal lamina propria and had increased systemic IL6, produced by CX3CR1+ MNPs, suggesting a mechanism to differentially respond to translocation commensals and pathogens by the mucsoal immune system. It has been assumed the neonatal response is one of immaturity and ignorance that lacks the ability to properly fight bacterial pathogens due to a state of immunosuppression until the immune system fully matures. However, my preliminary data indicates a sophisticated innate immune system able to sense distinct bacterial differences and perceive potential pathogenic threats. My hypothesis based on recent clinical findings of a cytokine signature unique to neonates including increased serum IL-6 is that this response is initiated by the MNP cells within the intestine that encounter the translocating bacteria. This project will utilize animal models, sepsis pathogens, and a variety of flow cytometry-based assays to explore the innate immune response to sepsis pathogens following translocation from the intestine. Following the completion of this project, I will understand the innate immune response following pathogen translocation, defining the dynamics of how CX3CR1 MNPs may contribute to systemic dissemination of bacteria, and how these processes may differ from the response following commensal translocation. Additionally, this work will allow for the development of interventions and preventative therapeutics specific for neonatal sepsis cases, by understanding the unique aspects of the neonatal response to gut originating bacterial pathogens.

Public Health Relevance

Following birth, the early life is marked by a time when neonates are susceptible to overwhelming inflammation in response to bacterial bloodstream infections, a disease known as neonatal sepsis. Recently is has been suggested gut-originating bacterial pathogens can translocate from the intestine to the body resulting in neonatal sepsis, though it remains unknown what cells contribute to bacterial translocation and how the neonatal immune system responds to gut-originating bacterial pathogens. This grant explores the innate immune response following bacterial translocation from the intestine in neonatal animals.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Small Research Grants (R03)
Project #
1R03DK122187-01A1
Application #
10055119
Study Section
Kidney, Urologic and Hematologic Diseases D Subcommittee (DDK)
Program Officer
Saslowsky, David E
Project Start
2020-07-10
Project End
2022-04-30
Budget Start
2020-07-10
Budget End
2021-04-30
Support Year
1
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905